Home › Research › Tau biomarkers
Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease
Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, Yébenes JG, del Ser T.. Archives of neurology, 2003-09-01
Topic: Amyloid, tau and blood-test diagnosis
Background Most patients with dementia with Lewy bodies (DLB) exhibit diffuse plaque-only pathology with rare neocortical neurofibrillary tangles (NFTs), as opposed to the widespread cortical neurofibrillary-tau involvement in Alzheimer disease (AD). Another pathological difference is the astrocytic and microglial inflammatory responses, including release of interleukins (ILs), around the neuritic plaques and NFTs in AD brains that are absent or much lower in DLB. We analyzed cerebrospinal fluid (CSF) markers that reflect the pathological differences between AD and DLB.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gómez-Tortosa, E., Gonzalo, I., Fanjul, S., Sainz, M. J., Cantarero, S., Cemillán, C., et al. (2003). Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Archives of neurology. https://doi.org/10.1001/archneur.60.9.1218
Vancouver
Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Archives of neurology. 2003. doi:10.1001/archneur.60.9.1218. PMID: 12975286.
BibTeX
@article{gomeztortosa2003-12975286,
author = {Gómez-Tortosa, E. and Gonzalo, I. and Fanjul, S. and Sainz, M. J. and Cantarero, S. and Cemillán, C. and Yébenes, J. G. and del Ser, T.},
title = {{Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease}},
journal = {Archives of neurology},
year = {2003},
doi = {10.1001/archneur.60.9.1218},
pmid = {12975286},
url = {https://doi.org/10.1001/archneur.60.9.1218}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Another pathological difference is the astrocytic and microglial inflammatory responses, including release of interleukins (ILs), around the neuritic plaques and NFTs in AD brains that are absent or much lower in DLB.
- We analyzed cerebrospinal fluid (CSF) markers that reflect the pathological differences between AD and DLB.
- Objective To determine CSF concentrations of tau, beta-amyloid, IL-1beta, and IL-6 as potential diagnostic clues to distinguish between AD and DLB.
- Methods We measured total tau, beta-amyloid1-42, IL-1beta, and IL-6 levels in CSF samples of 33 patients with probable AD without parkinsonism, 25 patients with all the core features of DLB, and 46 age-matched controls.
Why it matters
This study measured CSF tau, beta-amyloid, IL-1beta, and IL-6 to see whether they could help distinguish Alzheimer's disease from dementia with Lewy bodies. It is a diagnostic comparison study and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants33
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of neurology) |
| Journal's citation record | 3 / 4 | Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 1 / 4 | 33 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 134 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.4 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Teodoro del Ser: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad Complutense de Madrid: institution h-index 656 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12975286) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.